FDA Issues Warning on Compounded Versions of Novo Nordisk's Semaglutide
AbbVie Exits Alzheimer's Program on Lack of Differentiation
Analyzing Eli Lilly and Co In Comparison To Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Amgen
Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events
Biogen-partnered Alzheimer's Therapy Fails to Clear EU Hurdle
Walt Disney, Eli Lilly, AST SpaceMobile, DexCom, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Novo Nordisk Shares Decline Amid Competitive Pressure
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Why Eli Lilly and Company Shares Are Moving Lower On Thursday
Market Whales and Their Recent Bets on AMGN Options
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Actinium Wins FDA Nod to Conduct Clinical Trial for Radiotherapy
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
Elon Musk Agrees With Former Executive Who Thinks 'Everyone' Has 'Strong' Opinions On Tesla Unlike In The Case Of Eli Lilly And LVMH
Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts
Eli Lilly and Co Analyst Ratings
Albemarle Is Out of Wells Fargo's Signature Picks
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On